Table 2.
Basic characteristics of participants.
| Characteristics | Categories | Experimental group (n = 64) | Control group (n = 65) | t/χ2 | P |
|---|---|---|---|---|---|
| Age, years | 45.64 ± 11.59 | 47.95 ± 11.96 | −1.115 | 0.267 | |
| Sex | Male | 35 (54.7) | 39 (60.0) | 0.372 | 0.595 |
| Female | 29 (45.3) | 26 (40.0) | |||
| Diagnosis | Nasopharyngeal carcinoma | 38 (59.4) | 37 (56.9) | 3.879 | 0.923 |
| Lymphoma or osteosarcoma | 10 (15.6) | 11 (16.9) | |||
| Upper gastrointestinal cancer | 8 (12.5) | 9 (13.9) | |||
| Gynecological or breast cancer | 8 (12.5) | 8 (12.3) | |||
| Treatment | Chemotherapy | 10 (15.6) | 13 (20.1) | 3.184 | 0.374* |
| Chemotherapy with radiotherapy | 50 (78.1) | 50 (76.9) | |||
| Surgery with chemotherapy | 4 (6.3) | 1 (1.5) | |||
| Surgery with chemotherapy and radiotherapy | 0 (0.0) | 1 (1.5) | |||
| Body mass index, kg/m2 | ≤18.4 | 5 (7.8) | 4 (6.2) | 0.964 | 0.617 |
| 18.5–24.9 | 45 (70.3) | 42 (64.6) | |||
| ≥25.0 | 14 (21.9) | 19 (29.2) | |||
| Coagulation functiona | |||||
| Platelet count | Low | 1 (1.6) | 0 (0.0) | 2.636 | 0.268 |
| Normal | 55 (85.9) | 61 (93.8) | |||
| High | 8 (12.5) | 4 (6.2) | |||
| APTT | Low | 4 (6.3) | 11 (16.9) | 3.575 | 0.097 |
| Normal | 60 (93.7) | 54 (83.1) | |||
| TT | Low | 1 (1.6) | 0 (0.0) | 1.024 | 0.496 |
| Normal | 63 (98.4) | 65 (100) | |||
| PT | Normal | 64 (100) | 64 (98.5) | 0.992 | 0.319 |
| High | 0 (0.0) | 1 (1.5) | |||
| Fibrinogen | Normal | 56 (87.5) | 60 (92.3) | 0.823 | 0.397 |
| High | 8 (12.5) | 5 (7.7) | |||
| D-dimers | Normal | 58 (90.6) | 62 (95.4) | 1.126 | 0.324 |
| High | 6 (9.4) | 3 (4.6) |
Data are presented as mean ± standard deviation or n (%).
aReference ranges: platelet count, 100–300 × 109/L; APTT, 22.5–34 s; TT, 14.0–21.0 s; PT, 9.8–13.5 s;
fibrinogen, 1.80–4.00 g/L; D-dimers, 0.00–0.55 μg/mL.
*Fisher’s exact test.
APTT, activated partial thromboplastin time; TT, thrombin time; PT, prothrombin time.